Introduction
============

The seven-transmembrane spanning G protein-coupled receptor (GPCR) family represent in humans, with more than 800 members, the largest family of cell surface proteins corresponding to about 3% of all genes. Although generally expressed at relatively low levels, every cell typically expresses at least one and in most cases several GPCRs at their cell surface. Not surprisingly, GPCRs are involved in all major biological processes ranging form cell migration, proliferation, inflammation, immunity, etc... GPCRs respond to a remarkable diversity of ligands ranging from photons, to ions, metabolites, amino acids, lipids, peptides, and proteins. Over the last 20 years, GPCRs have been among the most tractable targets for the development of therapeutic small molecule drugs.

The canonical signaling pathway of GPCRs involves monomeric receptors, heterotrimeric G proteins, and various effector systems. Subsequently, several features have been added to this basic concept. Notably, addition of GPCR interacting proteins other than G proteins opened the possibility of fine-tuning of signaling in a receptor subtype- and tissue-specific manner. Moreover, alternative, G protein-independent, i.e., β-arrestin-dependent, signaling pathways have been described. Further diversity has been introduced by the notion that GPCRs might not only exist as monomeric peptides but can also cluster in dimeric or oligomeric structures. The current review gives a short overview of the proposed functions of GPCR oligomers and discusses the biological relevance and participation of such complexes in functional crosstalk. In the second part, examples of GPCR oligomers in the neuro-endocrine system will be critically assessed.

GPCR Oligomers, what are They Good for?
=======================================

The concept of GPCR di(oligo)merization has raised considerable interest over the last 20 years. Supporting evidence comes form numerous reports using biochemical, biophysical, and functional assays (see Bouvier, [@B19]; Angers et al., [@B6] for review). Whereas the first pioneering studies considered the clustering of one specific GPCR into homomers, it become rapidly evident that different types of GPCRs might also assemble into heteromers, thus broadening the potential impact of GPCR oligomerization considerably (see Prinster et al., [@B92]; Milligan, [@B80] for review). Having accepted that GPCR dimers exist, the question of the functional significance of these dimers arises.

In the case of obligatory dimers, the functional significance of GPCR dimers is obvious. Indeed, early studies showed that co-expression of GABA~B1~ and GABA~B2~ subunits is necessary for the functional expression of the GABA~B~ receptor (Jones et al., [@B64]; White et al., [@B120]). Subsequently, it was shown that the GABA~B1~ subunit binds the natural ligand whereas the GABA~B2~ subunit is necessary for G protein coupling and cell surface expression of the heteromeric complex. Similar observations have been made for sweet and umami taste receptors (Nelson et al., [@B84], [@B83]). The issue is however more complex for non-obligatory dimers. The major difficulty resides in preparing pure monomeric and dimeric GPCR samples rather than measuring their biological function. An elegant way to determine the function of monomeric GPCRs was achieved by the reconstitution of purified β2AR in high-density lipoprotein phospholipid bilayer particles. Importantly, the geometry of these particles allows only integration of monomeric receptor protomers. Addition of purified heterotrimeric G proteins showed that G protein activation was as efficient as in intact cells (Whorton et al., [@B121]). Similar conclusions were drawn by two further studies using rhodopsin as model receptor (Bayburt et al., [@B11]; Ernst et al., [@B41]). These studies show that monomeric GPCRs are sufficient for G protein activation leaving the question of the function of GPCR dimers unanswered.

The role of GPCR dimer formation is clear in non-obligatory heteromers with distinct functional properties (Prinster et al., [@B92]; Milligan, [@B80]). GPCR heteromerization between orphan GPCRs for which no natural ligand is known and non-orphan GPCRs with known ligand is very interesting in the sense that it might define the function of orphan GPCRs. The existence of ligand-independent functions of some of the more than 100 still orphan GPCRs has indeed been determined in several heteromers containing non-orphan GPCRs (Levoye et al., [@B74]).

A number of studies have suggested that GPCR oligomerization may be important in cell surface delivery implying that oligomerization occurs early in the biosynthetic pathway (Bulenger et al., [@B21]). According to this model, successful oligomerization is part of the quality control process. A prominent example is the GABA~B~ receptors, where the GABA~B2~ subunit controls the proper cell surface expression of GABA~B1~.

Formation of functional dimers offers the possibility for allosteric regulation of one protomer by the other. Several reports confirmed indeed the existence of allosteric interactions between the two orthosteric binding sites within a dimer. Negative and positive allosteric effects have been reported (Durroux, [@B39]).

Allosteric interactions between the protomers of GPCR dimers imply asymmetry within the GPCR cluster. The concept of asymmetric dimers on the level of the ligand binding site can be further extended toward G protein coupling or binding of GPCR interacting proteins (GIPs) in general. Assymetric binding of G proteins to only one of the two protomers was shown for several GPCRs. In the case of GABA~B~ receptors, ligand binding to the GB1 subunit *trans*-activates the GB2 subunit that binds to the G proteins (Galvez et al., [@B49]). In contrast, in the leukotriene B4 BLT1 receptor the same protomer binds the ligand and activates the G protein in a *cis* manner, therefore questioning the function of the second protomer (Baneres and Parello, [@B8]). Recent studies on the melatonin MT~1~ receptor complex with G~i~ proteins and the regulator of G protein (RGS) 20 suggest that one protomer binds to the G protein whereas the second protomer binds to other GIPs, RGS20 in the present case. These results provide an additional justification for dimer formations and for the fine-tuning of GPCR signaling through GIPs.

Functional Crosstalk Between GPCRs with or without Dimerization
===============================================================

Signal integration between different hormones is a common feature of the endocrine system. Indeed, each cell expresses typically several GPCR subtypes that integrate different hormonal signals in time and space to produce an adequate cellular response. The ability of one hormone, acting on a specific GPCR, to modulate the function of a second GPCR does not inherently imply heteromerization between these two GPCRs. Indeed receptor heteromerization represent only one out of several ways of functional crosstalk at the cellular level (Figure [1](#F1){ref-type="fig"}). Heterologous sensitization and desensitization, i.e., through activation of protein kinase A or C, are often involved in the integration of cellular signals (Jockers et al., [@B63]). Crosstalk may also occur at receptor-proximal levels through competition for a common and limited G protein pool as indicated in a recent study on the virally encoded BILF1 receptor (Nijmeijer et al., [@B85]). Clustering of this G~i~-coupled constitutively active receptor with either the chemokine CXCR4 or the histamine H~4~ receptor appears to sequester G~i~ proteins away from the two latter receptors impairing their G~i~-dependent signal transduction. Furthermore, potentiation of cellular signals at the level of Gβγ subunits has been reported in a number of studies (see Prezeau et al., [@B91] for review). Stimulation of G~i~-coupled GABA~B~ receptor is known to potentiate Ca^2+^ signaling of the G~q~-coupled mGlu~1a~ receptor, in cortical neurons co-expressing both receptors (Hirono et al., [@B58]). Studies in transfected HEK293 cells confirmed this functional crosstalk and indicated that Gβγ subunits, liberated upon activation of GABA~B~ receptor, are responsible for the Ca^2+^ potentiation in the absence of any evidence of receptor heteromerization (Rives et al., [@B98]). Importantly, similar potentiating effects can be seen between other G~i~- and G~q~-coupled GPCRs suggesting a general mechanism of signal integration.

![**Functional versus physical interaction of GPCRs**. **(I)** In the absence of any physical or functional interaction, the activation of two different GPCRs induces two independent signaling pathways A and B, which consequently result in two independent effects 1 and 2. **(II)** Physical interaction of two different GPCRs results in the activation of the heteromer-specific signaling pathway C that will be responsible of a downstream effect 3. **(III)** In the absence of physical interaction, a functional interaction can be observed when signaling pathways A and B crosstalk to produce effect 4.](fendo-02-00002-g001){#F1}

A further mechanism of cellular crosstalk was recently suggested for the corticotropin-releasing factor receptor 1 (CRF~1~) and serotonin 5-HT~2~ receptors (Magalhaes et al., [@B76]) Cellular 5-HT~2~ responses and serotonin-dependent anxiety were sensitized by CRF stimulation. Sensitization of 5-HT~2~ responses correlated with increased cell surface expression of 5-HT~2~ receptors, which are known to constitutively internalize. Interestingly this effect was dependent on the presence of functional PDZ domain binding motifs of the CRF~1~ and 5-HT~2~ receptors and intact endocytotic and recycling pathways suggesting a putative scaffolding function of multi-PDZ domain-containing proteins to facilitate recycling of 5-HT~2~ and CRF~1~ receptors.

Crosstalk at the level of GPCR oligomers has been demonstrated in several cases. For example, discovery of heteromer-specific signaling pathways (Rashid et al., [@B93]) and heteromer-selective ligands strongly suggest the importance of opioid receptor (OR) heteromers in physiology (Waldhoer et al., [@B118]). Unique heteromer-specific cellular responses have been also associated with the 5-HT~2A~/mGlu~2~ heteromer, which has been implicated in psychosis (Gonzalez-Maeso et al., [@B52]). By constructing chimeric receptors between mGlu~2~, which interacts with 5-HT~2A~ receptors and mGlu~3~, which does not interact with 5-HT~2A~, the authors convincingly showed that the cellular responses were exclusively dependent on the formation of 5-HT~2A~/mGlu~2~ heteromers.

Collectively, these data show that functional crosstalk may occur at different levels of cellular signaling and trafficking that may or may not depend on GPCR heteromerization. The examples presented in the chapter "Examples in the neuro-endocrine system" will be analyzed in respect of the molecular level of crosstalk.

Biological Significance of GPCR Heteromerization -- Criteria
============================================================

Evidence for the formation of GPCR heteromers is mostly based on observations made in transfected cell lines raising the question of the biological significance of these complexes. Nevertheless, an increasing number of articles provide evidence of GPCR heteromerization in endogenous tissues, some of which will be discussed in the next chapter. To provide some guidance in defining the physiological relevance of GPCR heterodimers, the International Union of Basic and Clinical Pharmacology (IUPHAR) released some recommendations in 2007 (Pin et al., [@B90]). The first criterion concerned the evidence for physical interaction (or proximity) of both receptors in native tissues or primary cells. This may be achieved by performing co-immunoprecipitation experiments with selective antibodies or energy transfer techniques between labeled ligands or antibodies. The second criterion requests evidence for heteromer-specific properties such as heteromer-specific signaling properties, the identification of heteromer-selective ligands and the presence of allosteric ligand binding properties. The third criterion recommends supporting evidence from knockout animals or RNAi technologies to further validate the possible functional role of heteromers *in vivo*. Obviously, none of these criteria alone provides conclusive evidence for the existence and functional significance of GPCR heteromers. The comity therefore proposes that at least two of the three criteria have to be fulfilled for the acceptance of GPCR heteromers.

Examples in the Neuro-Endocrine System
======================================

G protein-coupled receptor oligomerization has become an extensively studied field. The current chapter will focus on the description of GPCR heteromers relevant in neuroendocrinology. A more extensive list of GPCR heteromers is provided in Table [1](#T1){ref-type="table"}. Complementary information on GPCR heteromerization may be also found in other recent expert reviews (Birdsall, [@B15]; Ferre et al., [@B46]; Rozenfeld and Devi, [@B100]).

###### 

**Non-exhaustive list of GPCR heteromers in the neuro-endocrine system**.

  Heterodimer            In vitro Physical interaction   In vivo Functional                                        interaction in vivo      References
  ---------------------- ------------------------------- --------------------------------------------------------- ------------------------ ------------------------------------------------------------------------------
  β~2~AR/EP~1~           BRET and co-IP                  --                                                        --                       McGraw et al. ([@B78])
  β~2~AR/κOR             co-IP                           --                                                        --                       Jordan et al. ([@B65])
  β~2~AR/μOR             co-IP                           --                                                        --                       Jordan et al. ([@B65])
  5- HT~2A~/D~2~         FRET                            --                                                        --                       Lukasiewicz et al. ([@B75])
  5-HT~1A~/Gal~1~        FRET                            --                                                        S and BP                 Borroto-Escuela et al. ([@B18]), Kehr et al. ([@B70])
  5-HT~2A~/mGlu~2~       co-IP and BRET                  co-IP frontal cortex samples                              S and B                  Gonzalez-Maeso et al. ([@B52])
  5-HT~4~/5-HT~2(A,B)~   --                              --                                                        S                        Derangeon et al. ([@B38])
  A~1~/A~2A~             BRET and co-IP                  co-IP rat striatum                                        B and S                  Ciruela et al. ([@B31])
  A~1~/mGlu~1α~          co-IP                           co-IP rat cerebellar synaptosomes                         S                        Ciruela et al. ([@B32])
  A~1~/P2Y~1~R           co-IP                           co-IP rat brain, hippocampus and human astroglial cells   S                        Yoshioka et al. ([@B125]), Tonazzini et al. ([@B113])
  A~2~/mGlu~5~           co-IP                           --                                                        S and BP                 Ferre et al. ([@B45]), Kachroo et al. ([@B67]); Adams et al. ([@B3])
  A~2~/mGlu~5~/D~2~      BRET and FRET                   co-IP rat striatum                                        S                        Cabello et al. ([@B22])
  A~2A~/D~2~             FRET and co-IP                  co-IP rat striatum and neuroblastoma                      S and BP                 Canals et al. ([@B23]), Tanganelli et al. ([@B109])
  AT~1~/β~2~AR           co-IP                                                                                     S                        Barki-Harrington et al. ([@B10])
  AT~1~/APJ              BRET and FRET and co-IP         −                                                         --                       Chun et al. ([@B29])
  AT~1~/B~2~             Not clear                       Not clear                                                 S                        AbdAlla et al. ([@B1]), Hansen et al. ([@B56])
  CB~1~/A~2A~            BRET                            co-IP rat striatum                                        S and BP                 Andersson et al. ([@B5]), Carriba et al. ([@B24]), Tebano et al. ([@B110])
  CB~1~/D~2~             FRET                            --                                                        B                        Marcellino et al. ([@B77]), Kearn et al. ([@B69]), Glass and Felder ([@B50])
  CB~1~/δOR              BRET                            --                                                        S                        Rios et al. ([@B95])
  CB~1~/κOR              BRET                            --                                                        S                        Rios et al. ([@B95])
  CB~1~/μOR              FRET and co-IP                  --                                                        S                        Rios et al. ([@B95]), Hojo et al. ([@B59]), Cichewicz ([@B30])
  CB~1~/OX~1~            FRET                            --                                                        --                       Hilairet et al. ([@B57]), Ellis et al. ([@B40])
  CCR5/μOR               co-IP                           --                                                        --                       Chen et al. ([@B27])
  CRF~1~/5-HT~2~         --                              --                                                        S and T                  Magalhaes et al. ([@B76])
  CXCR4/δOR              FRET                            --                                                        S                        Pello et al. ([@B86])
  CXCR4/κOR              --                              --                                                        S and BP                 Finley et al. ([@B48])
  D~1~/D~2~              co-IP                           co-IP and new Gq coupling                                 S                        Lee et al. ([@B73]), Rashid et al. ([@B93])
  D~1~/H~3~              BRET                            --                                                        S and BP                 Ferrada et al. ([@B44])
  D~1~/μOR               BRET                            --                                                        S and E                  Tien et al. ([@B112]), Becker et al. ([@B12])
  D~2~/H~3~              BRET                            --                                                        S and BP                 Ferrada et al. ([@B44])
  D~2~/SST~2~            FRET                            photo-bleaching FRET in rat striatum                      Bivalent ligands and S   Baragli et al. ([@B9]), Jaquet et al. ([@B61])
  D~2~/SST~5~            photo-bleaching FRET                                                                      S                        Rocheville et al. ([@B99])
  D~5~/D~2~              BRET                            --                                                        S                        So et al. ([@B106])
  EP~1~/D~1~             --                              --                                                        S                        Kitaoka et al. ([@B71])
  EP~1~/D~2~             --                              --                                                        S                        Kitaoka et al. ([@B71])
  ET~A~/ET~B~            FRET                            --                                                        --                       Evans and Walker ([@B42])
  GABA~B1~/CaS           co-IP                           co-IP brain lysates                                       S and E                  Chang et al. ([@B26])
  GABA~B2~/M~2~          FRET and TIRF                   co-IP cortex                                              --                       Boyer et al. ([@B20])
  GHSR/D~1~              --                              --                                                        --                       Chow et al. ([@B28])
  GHSR/EP~1~             BRET and co-IP                  --                                                        --                       Chow et al. ([@B28])
  GHSR/IP                BRET and co-IP                  --                                                        --                       Chow et al. ([@B28])
  GHSR/MC~3~             FRET and ELISA                  --                                                        --                       Rediger et al. ([@B94])
  GHSR/NTS~1~            co-IP                           --                                                        S                        Takahashi et al. ([@B108])
  GHSR/TP                BRET and co-IP                  --                                                        --                       Chow et al. ([@B28])
  IP/TP                  co-IP                           --                                                        --                       Wilson et al. ([@B122])
  MC~4~/GPR7             FRET and ELISA                  --                                                        --                       Rediger et al. ([@B94])
  MC~4~/MC~4~ D90N       FRET and ELISA                  --                                                        S                        Biebermann et al. ([@B14])
  NK~1~/μOR              BRET and co-IP                  --                                                        S and BP                 Ripley et al. ([@B96]), Pfeiffer et al. ([@B88])
  T1R1/T1R3              co-IP and ligand binding        Rescue of T1R3 KO mice                                    S                        Nelson et al. ([@B84], [@B83]), Xu et al. ([@B124])
  T1R2/T1R3              co-IP and Ligand binding                                                                  S                        Nelson et al. ([@B84], [@B83]), Xu et al. ([@B124])
  V~1A~/OT               co-IP and BRET                  --                                                        --                       Terrillon et al. ([@B111])
  V~2~/OT                co-IP and BRET                  --                                                        --                       Terrillon et al. ([@B111])
  β~1~AR/β~2~AR          co-IP                           --                                                        S                        Zhu et al. ([@B128])
  Zhu et al. ([@B128])                                                                                                                      

*This table enumerates the major GPCR heteromers and details the, in vitro and in vivo, evidence for physical interaction, if present. S, signaling modulation; T, trafficking modulation; B, binding modulation; E, expression modulation; BP, Behavioral or pain modulation in mice; BRET, bioluminescence resonance energy transfer; FRET, fluorescence resonance energy transfer; co-IP, co-immunoprecipitation; βAR, beta adrenergic receptor; EP~1~, prostanoid receptor 1; κOR, kappa opioid receptor; μOR, mu opioid receptor; δOR, delta opioid receptor; 5-HT~2~, serotonin receptor 2; D~2~, dopamine receptor 2; 5-HT~1~, serotonin receptor 1; 5-HT~4~, serotonin receptor 4; Gal, galanin receptor; mGlu, mGlutamate receptor; A, adenosine receptor; P2YR, purinergic P2Y receptors; AT, angiotensin receptor; APJ, apelin receptor; B, Bradikinin receptor; CB, canabinoid receptor; OX, orexin receptor; CCR5, C-C chemokine receptor type 5; CXCR4, C-X-C chemokine receptor type 4; CRF~1~, corticotrophin releasing factor receptor subtype 1; H~3~, histamine receptor 3; SST, somatostatin receptor; ET, endothelin receptor; GABA~B~, γ-aminobutyric acid; CaS, calcium-sensing receptor; M~2~, muscarinic receptor 2; GHSR, ghrelin receptor; IP, prostaglandin (prostacyclin) receptor; MC, melanocortin receptor; NTS, neurotensin receptor; TP, thromboxane receptor; NK~1~, substance P receptor; T1R, taste receptor 1; V, vasopressin receptor; OT, oxytocin receptor*.

GPCR heteromers in the central nervous system
---------------------------------------------

G protein-coupled receptors are widely distributed in the nervous system, and mediate key physiological processes including cognition, mood, appetite, pain, and synaptic transmission. The important role of GPCRs in central nervous system (CNS) disorders is outlined by the great quest of pharmaceutical companies for drug discovery. Several GPCRs, in particular the metabotropic glutamate, adenosine, dopamine as well as serotonin receptor, and cannabinoid receptors, were shown to be implicated in CNS disorders such as Parkinson, Alzheimer, schizophrenia, depression, and psychosis. Despite the lack of direct evidence for the implication of GPCR heteromers in neuropathologies, several examples in the literature show the importance of heteromerization in receptor functions suggesting that alterations in GPCR crosstalk can directly impact health.

### Opioid and Cannabinoid Receptor Heteromers

Opioid receptors bind endogenous peptides with effects resembling those of opiate drugs and are very well known for their roles in pain, analgesia and reward. Heteromerization between the different OR subtypes was extensively studied over the last 20 years (see van Rijn et al., [@B117] for review) with some evidence *in vivo*. For example, the δ/κ OR selective ligand, the 6′-guanidinonaltrindole (6′-GNTI), is an analgesic and has the unique property of preferentially activating OR heterodimers over the corresponding homomers, indicating that OR heteromers are functionally relevant *in vivo* (Waldhoer et al., [@B118]). In the current review we will address only examples of OR heteromerization with other GPCRs.

Opiates and exogenous cannabinoids are analgesics used for the treatment of patients with neuropathic pain. Considerable behavioral, anatomical, and biochemical evidence describe similarities between the OR and the cannabinoid receptor systems. The first study to suggest direct physical interactions between the cannabinoid CB~1~ receptor and κOR and δOR (CB~1~/κOR and CB~1~/δOR) was conducted in transfected cells by Rios et al. ([@B95]). The authors identified a reciprocal antagonistic relationship between the two receptors in transfected cells and in native tissues exposed to increasing concentrations of an agonist for one receptor along with non-activating concentrations of an agonist for the other receptor. Another study showed, in 2008, a direct interaction between CB~1~ and μOR using FRET and co-immunoprecipitation experiments in CHO cells exogenously expressing both receptors (Hojo et al., [@B59]). *In vivo*, functional interaction of these receptors is very well exemplified by 9-tetrahydrocannabinol, the major psychoactive constituent of marijuana, which enhances the potency of opioids such as morphine in animal models (Cichewicz, [@B30]). Moreover, anatomical studies confirmed the co-localization of μOR and CB~1~ in common somatodendritic compartments of catecholaminergic neurons in the *locus coeruleus*, the center of opiate addiction and withdrawal, and also revealed CB~1~-positive axon terminals forming synaptic contact with μOR-containing dendrites (Scavone et al., [@B105]).

Recently, ORs were shown to interact functionally with chemokine receptors (Salanga et al., [@B103]). CXCR4 is able to cross-desensitize the chemotaxis and calcium mobilization response as well as analgesia associated with κOR. Activation of CXCR4 with CXCL12 induces desensitization of κOR and this leads to an impairment of analgesic activity *in vivo* (Finley et al., [@B48]). Using FRET, CXCR4 was shown to form heteromeric complexes with δOR. Intriguingly, simultaneous application of δOR and CXCR4 agonists to human monocytes (MM-1 cells) expressing both receptors endogenously, abolished functional effects observed upon treatment of these cells with either agonist alone (Pello et al., [@B86]).

CCR5 was reported to interact physically, *in vitro*, with μOR using co-immunoprecipitation assays inducing cross desensitization of the receptor without modulation of receptor internalization. DAMGO (μOR agonist) and RANTES induced chemotaxis in CHO cells co-expressing both receptors. Preincubation with either DAMGO or RANTES inhibited chemotaxis caused by the other ligand. Moreover, DAMGO pretreatment enhanced phosphorylation of CCR5 and reduced RANTES-promoted GTPγS binding suggesting heterologous desensitization (Chen et al., [@B27]).

Several different GPCRs are implicated in the regulation of striatal functions. Notably, *in vivo* functional crosstalks have been reported between dopamine and ORs. As an example, methamphetamine-induced *zif*268 (transcription factor also known as Egr1, Early Growth Response Protein 1) expression was abolished in μOR-knockout mice in which dopamine receptors were blocked by haloperidol. However, the expression of zif268 mRNA was not altered in μOR knockout mice without blockade of dopamine receptors or in wild-type mice with blockade of dopamine receptors (Tien et al., [@B112]). These results suggest a crosstalk between the μ-opioid system and the dopamine system in the modulation of the expression of *zif*268 induced by methamphetamine. D~1~ knockout mice were shown to have a reduced μOR expression in striatal patches without alterations in κOR and δOR expression patterns (Becker et al., [@B12]). Co-localization of these receptors was shown in rat striatal and cortical neurons, however direct interactions were only reported in transfected cells using the BRET assay (Juhasz et al., [@B66]).

Another example is the μOR and the substance P (NK~1~) receptor, which is highly expressed in brain regions implicated in depression, anxiety, and stress. They are also present in the *nucleus accumbens*, which mediates the motivational properties of drugs of abuse including opioids. The rewarding effects of morphine are absent in mice lacking NK~1~ suggesting that these receptors are critical for the reinforcing properties of morphine, and for adaptive responses elicited by repeated opiate administration (Ripley et al., [@B96]). Direct interaction between NK~1~ and μOR was reported *in vitro* and functional characterization of cells expressing both receptors revealed cross-modulation of receptor internalization and desensitization (Pfeiffer et al., [@B88]).

Cannabinoid receptors family remain one of the most important GPCR drug discovery targets due to the intense interest in CB~1~ receptor antagonists for treating obesity and the metabolic syndrome. Heteromerization of CB~1~ in the context of metabolism will be discussed later. The literature reports many examples of functional interaction between cannabinoid and dopamine receptors. Functional antagonism was shown in rat brain where the CB~1~ agonist CP55,940 reduced the affinity of D~2~ agonist binding sites in the dorsal and ventral striatum. Similarly, *in vivo* administration of CP55,940 inhibited D~2~-promoted locomotor activity (Marcellino et al., [@B77]). *In vitro*, heteromer formation was demonstrated using FRET (Marcellino et al., [@B77]). Co-expression of both receptors in HEK293 cells showed that co-stimulation of D~2~ and CB~1~ results in a switch of G protein coupling preference of these G~i/o~-coupled receptors toward the pertussis toxin-insensitive G~αs~ protein (Kearn et al., [@B69]). Similar observations have been reported in primary striatal neuron cultures (Glass and Felder, [@B50]) supporting the physiological relevance of D~2~/CB~1~ heteromer formation.

In the last few years, it has been suggested that A~2A~ receptors could exert a permissive role on CB~1~ function in a way that a basal adenosinergic tone would be important for cannabinoid-mediated effects. Specifically, it has been demonstrated that the ability of a CB~1~ agonist to inhibit motor activity requires the presence and the activation of A~2A~ (Andersson et al., [@B5]; Carriba et al., [@B24]). The activation state of A~2A~ seems also to regulate synaptic effects of CB~1~, which is partly dependent on mGlu~5~ (Tebano et al., [@B110]). Heteromer formation between CB~1~ and A~2A~ was shown *in vitro*, in cells exogenously expressing both receptors using BRET and, *in vivo*, by immunoprecipitation assays in rat striatum suggesting that heteromer formation may participate in the functional crosstalk between these two receptors (Carriba et al., [@B24]).

### Adenosine, Dopamine, and Glutamate Receptor Heteromers

Adenosine activates four GPCRs, A~1~, A~2A~, A~2B~, and A~3~, which are widespread throughout the body. They are involved in a variety of physiological processes and pathologies including neurological, cardiovascular, inflammatory diseases, and cancer (see Trincavelli et al., [@B115] for review).

Heteromerization between the different adenosine receptor subtypes is exemplified by the A~1~/A~2A~ heteromer, which was reported *in vitro* and *in vivo* in 2006 by Ciruela et al. ([@B31]). Immunogold detection and co-immunoprecipitation experiments confirmed the heteromer formation in rat striatal glutamatergic nerve terminals. The authors showed that A~2A~ activation reduces the affinity of A~1~ for agonists, which might explain the stimulatory effect of adenosine on glutamatergic neurotransmission at higher ligand concentrations. Moreover, the authors speculate about a possible role of A~1~/A~2A~ heteromers in the tolerance to the psychostimulant effects of caffeine (Ciruela et al., [@B31]).

Using co-immunoprecipitation assays Ciruela et al. ([@B32]) showed a subtype-specific interaction between mGlu~1α~ and A~1~ receptors in both rat cerebellar synaptosomes and co-transfected HEK293 cells. This heteromer was reported to be implicated in neuroprotection suggesting a potential role in neurodegenerative diseases such as Alzheimer. Importantly, the timing of mGlu~1α~ and A~1~ receptor activation is very important to achieve a maximal effect in adenosine- and glutamate-mediated neuroprotection/neurodegeneration (Ciruela et al., [@B32]).

Purinergic P2Y receptors are involved in neuromodulation and neuron--glia interactions and respond to a wider range of agonists, including di- or tri-phosphates of nucleosides, and uridine diphosphate-glucose. The P2Y~1~ subtype has been reported to form heteromers with the A~1~ receptor *in vivo* as determined by co-localization and co-immunoprecipitation experiments in rat brain (Yoshioka et al., [@B125]), rat hippocampus (Tonazzini et al., [@B114]), and in human astroglial cells (Tonazzini et al., [@B113]). P2Y~1~ stimulation impaired the potency of A~1~ coupling to G proteins, whereas the stimulation of A~1~ increased the functional responsiveness of P2Y~1~, indicating a functional interaction between these receptors in rat hippocampus (Tonazzini et al., [@B114]).

Several reports highlight the physical and functional interaction between A~2~ and D~2~ receptors. BRET and FRET assays as well as co-immunoprecipitation in neuroblastoma cells and striatum indicate formation of A~2~/D~2~ heteromers (Canals et al., [@B23]). It was also reported that A~2A~ receptor antagonists increase locomotion in reserpinized (dopamine-depleted) mice and produce contralateral rotational behavior in rats only after the treatment with sub-threshold doses of the D~2~-like receptor agonist quinpirole (Tanganelli et al., [@B109]).

A physical interaction between A~2~ and mGlu~5~ was shown *in vitro* by co-immunoprecipitation. Simultaneous stimulation of cells co-expressing both receptors led to a synergistic increase in ERK phosphorylation (Ferre et al., [@B45]). *In vivo*, the anti-Parkinsonian effects of mGlu~5~ antagonists, known to increase motor control, were potentiated by an A~2A~ antagonist confirming a functional interaction between these two receptors (Kachroo et al., [@B67]). A combination of a sub-threshold dose of SCH 58261 (A~2A~ antagonist) with a sub-threshold dose of MTEP (mGlu~5~ antagonist) reduced alcohol self-administration (Adams et al., [@B3]). In addition, A~2A~ and mGlu~5~ seem to form higher order oligomeric complexes with D2. Cabello et al. ([@B22]) were able to show *in vitro* using BRET and FRET assays as well as co-immunoprecipitation the presence of the latter three receptors in the same complex. Similar results were obtained in rat striatum homogenates (Cabello et al., [@B22]).

Dopamine is a neurotransmitter in many brain regions, and regarding Parkinson disease -- the most important is the striatum. In addition, relevant studies regarding receptor oligomerization are described in nucleus accumbens, i.e., a nucleus of the striatum. Dopamine binds and activates five types of receptors, D~1~, D~2~, D~3~, D~4~, and D~5~. The literature reports many examples of dopamine subtype heteromerization and postulate their implication in neuropathologies such as Parkinson and dyskinesia (Missale et al., [@B81]). D~1~/D~2~ heteromers are convincingly demonstrated *in vivo* by co-immunoprecipitation (Lee et al., [@B73]). Whereas D~1~ and D~2~ homomers are coupled to G~s~ and G~i~ proteins, respectively, D~1~/D~2~ heteromers are coupled to G~q/11~ when both protomers are activated. Activation of this heteromer-specific G~q/11~ pathway increases levels of calcium/calmodulin-dependent protein kinase IIα in the nucleus accumbens, unlike activation of the G~s~-coupled D~1~ receptors, indicating a mechanism by which D~1~/D~2~ may contribute to synaptic plasticity (Rashid et al., [@B93]).

Recently, D~1~ and D~2~ were reported to form heteromeric complexes with histamine H~3~ (but not H~4~) receptors *in vitro* using BRET. Functional interaction in mice is suggested in light of the important role of postsynaptic H~3~ receptors in the modulation of dopaminergic transmission by means of a negative modulation of D~2~ receptor function. Indeed, selective H~3~ receptor agonists inhibit D~1~- and D~2~-promoted locomotor activity and the H~3~ receptor antagonist thioperamide has a potentiating effect. Moreover, radioligand binding experiments in striatal membrane preparations showed that activation of H~3~ decreased the binding affinity of D~2~ (Ferrada et al., [@B44]).

Pituitary tumors express both somatostatin and dopamine receptors (Colao et al., [@B33]). D~2~ and somatostatin SST~2~ receptors are co-localized in three different brain regions including the cerebral cortex, striatum, and substantia nigra. *In vivo*, D~2~/SST~2~ heteromer formation was confirmed in rat striatal neurons using photo-bleaching FRET (Baragli et al., [@B9]). Another evidence supporting D~2~/SST~2~ formation comes from the high efficacy of bivalent ligands, designed to target somatostatin and dopamine receptors, on the inhibition of growth hormone (GH) and prolactin secretion from GH-secreting pituitary adenomas, which are partially responsive to somatostatin analog therapy (Jaquet et al., [@B61]).

The literature reports several studies pinpointing a functional crosstalk between the prostanoid receptor EP~1~ as well as D~1~ and D~2~ receptors without evidences for physical interactions. EP~1~ is expressed in more than one-half of medium spiny neurons in the striatum, and its ligand, prostaglandin E~2~ (PGE~2~) is produced in the striatum in response to stimulation with a D~1~ or D~2~ agonist. The PGE~2~--EP~1~ pathway facilitates both D~1~ and D~2~ signaling as indicated by the Thr34 phosphorylation of the dopamine- and cAMP-Regulated PhosphoProtein 32 (DARPP-32) *in vitro* in striatal slices. EP~1~-knock out mice exhibit a significant suppression of hyperlocomotion induced by cocaine or SKF81297, a D~1~ agonist, and significant attenuation of catalepsy induced by raclopride, a D~2~ antagonist (Kitaoka et al., [@B71]).

### GABA Receptor Heteromers

GABA~B~ are critical receptors in the CNS, where their function is mainly the suppression of neuronal activity. The GABA~B1~/GABA~B2~ heteromer, is one of the best characterized examples of GPCR heteromerization as detailed above. There is also some evidence for the formation of heteromers between GABA~B1~ and the calcium-sensing receptor (CaS) *in vitro* and in hippocampal neurons. CaS receptors control systemic calcium balance *via* the regulation of parathyroid hormone secretion and renal calcium excretion. Heteromer formation seems to modulate the expression of CaS as expression of the CaS is increased in brain lysates of GABA~B1~ knockout mice and in cultured hippocampal neurons (Chang et al., [@B26]).

GABA~B2~ was recently shown to interact functionally and physically with muscarinic M~2~ receptors. *In vitro*, a combination of FRET and TIRF microscopy detected the heteromers at the cell surface. GABA~B2~ and M~2~ are both localized in the somatosensory cortex and are shown to interact *in vivo* by co-immunoprecipitation. In PC12 cells, GABA~B2~ expression rescues M~2~ surface expression, M~2~-induced activation of GIRKs, and inhibition of cAMP production (Boyer et al., [@B20]).

### Serotonin Receptor Heteromers

Serotonin (5-HT) receptors represent one of the largest subfamilies of GPCRs. There are 14 different 5-HT receptor subtypes widely distributed throughout the peripheral and CNS, representing therapeutic targets for drugs used to treat anxiety, depression, schizophrenia, obesity, and other disorders (Millan et al., [@B79]).

Alterations in either serotonin or dopamine neurotransmission seems to be implicated in many human neurological and psychiatric disorders, including depression, anxiety, and schizophrenia (de Almeida et al., [@B37]). Recently, formation of 5-HT~2A~/D~2~ heteromers was reported *in vitro* using FRET but the functional properties of this complex are not known. Nevertheless, 5-HT~2A~ and D~2~ receptors are co-localized in the medial prefrontal cortex as well as in the pars reticulate of the substantia nigra in rat, suggesting, at least, the possibility of functional crosstalk between these two receptors *in vivo* (Lukasiewicz et al., [@B75]).

The 5-HT~2A~/mGlu~2~ heteromer plays a role in anxiety and constitutes one of the most interesting examples of GPCR heteromerization reported so far. Compelling pharmacological and biochemical evidence *in vivo* confirmed the physical interaction between 5-HT~2A~ and mGlu~2~. Moreover, the metabotropic glutamate agonist, LY379268 increases the affinity of different hallucinogens for the 5-HT~2A~ receptor-binding site but also, a selective 5-HT~2A~ receptor agonist decreases the affinity of different agonists for the mGlu~2~ receptor-binding site (Gonzalez-Maeso et al., [@B52]).

Galanin is co-expressed with and modulates serotonin and noradrenaline release, two neurotransmitters implicated in depression. Stimulation of galanin GAL~1~ and/or GAL~3~ receptors results in a depression-like phenotype, while activation of the GAL~2~ receptor attenuates depression-like behavior (Kuteeva et al., [@B72]). 5-HT~1A~ and GAL~1~ interact with each other *in vitro* as demonstrated by FRET. After simultaneous activation of both receptors, G~i~ and MAPK signaling did not show any additive or synergistic effects indicating that activation of each receptor alone is sufficient to reach maximal signaling capacity for these specific pathways (Borroto-Escuela et al., [@B18]). However, an antagonistic effect of GAL~1~ activation on 5-HT~1A~-induced hippocampal serotonin release and hypothermia and locomotor activity were shown in the rat brain (Kehr et al., [@B70]).

Another example of functional crosstalk with no evidence, at least for now, of physical interaction has been described for CRF~1~ and 5HT~2~ receptors involved in anxiety as detailed above (Magalhaes et al., [@B76]).

GPCR heteromers in the cardiovascular--renal system
---------------------------------------------------

The most commonly studied and clinically targeted cardiac GPCRs include adrenergic, angiotensin, endothelin, and adenosine receptors. Drugs, targeting adrenergic, and angiotensin receptor signaling pathways alone, account for the majority of prescriptions for cardiovascular diseases (Salazar et al., [@B104]).

Angiotensin II (AngII) causes vasoconstriction both by a direct action on smooth muscle cells and, indirectly, through the facilitation of noradrenaline release from postganglionic sympathetic neurons. AngII binds to two main receptors, AT~1~ and AT~2~. *Via* stimulation of AT~1~ receptors, AngII causes virtually all of its physiological actions, namely the cardiovascular, neuronal, renal, endocrine, and hepatic effect see (Guimaraes and Pinheiro, [@B54]) for review. Bradykinin (BK), an endogenous vasoactive peptide mainly produced from plasma with a physiological role in inflammation and nociception, binds two main receptors, B~1~ and B~2~ (Fincham et al., [@B47]). AbdAlla et al. ([@B2]) reported functional and physical interaction between AT~1~ and B~2~ receptors with major implications in pre-eclampsia and hypertensions. In the cortical thick ascending limb in the kidney, BK exerts negative modulatory effects on AngII-induced calcium responses dependent on tyrosine kinase and MAPK pathways. In the presence of BK AngII-induced sodium transport is suppressed (Hus-Citharel et al., [@B60]). The AT~1~/B~2~ heteromer has also been suggested to contribute to AngII hyper-responsiveness of mesangial cells in experimental hypertension (AbdAlla et al., [@B1]). However, the existence of AT~1~/B~2~ heteromers has been questioned by several groups suggesting that the documented *in vivo* crosstalk between these two hormones is most likely based on a functional rather than physical interactions (Hansen et al., [@B56]).

AT~1~/β~2~AR heteromers were described in mouse cardiac myocytes transfected with the corresponding cDNAs. The main functional consequence of this interaction is the enhancement of agonist-induced β~2~AR signaling and the silencing of the spontaneous activation of β~2~AR, suggesting that heteromerization mutually stabilizes both receptor subtypes in their respective inactive conformations in the absence of agonist. *In vivo*, selective blockade of β~2~AR in mouse cardiomyocytes inhibits angiotensin-induced contractility and administration of the AT~1~ antagonist valsartan reduces the maximal response to catecholamine-induced elevation of heart rate (Barki-Harrington et al., [@B10]), further supporting the physiological relevance of heteromerization.

Another heteromeric partner described for AT~1~ is the apelin receptor (APJ). Apelin seems to be an important factor in the regulation of vascular tone and cardiovascular function (Kalea and Batlle, [@B68]). AT~1~ was shown to physically interact with APJ *in vitro* by BRET, FRET, and co-immunoprecipitation assays. Whereas *in vivo* evidence for AT~1~/APJ heteromer formation is still lacking, many examples support an *in vivo* functional crosstalk. In apelin knockout mice, exogenous Ang II induces atherosclerosis and abdominal aortic aneurysm formation while co-infusion of apelin abrogated these effects. Moreover, in a vein graft mode, apelin treatment rescued AngII-mediated increase in neointimal formation and vascular remodeling (Chun et al., [@B29]).

Adrenergic receptors are responsible for translating chemical messages from the sympathetic nervous system into cardiovascular responses. Three β-adrenergic receptor subtypes are found in the mammalian heart β~1~, β~2~, and β~3~-AR (Salazar et al., [@B104]). Heteromerization between the different subtypes has been described and is implicated in many cardiovascular functions. For example, alterations in receptor pharmacology and function were seen in intact adult mouse cardiomyocytes lacking β~1~AR and β~2~AR, where heteromerization reduced spontaneous receptor activity and enhanced responsiveness to catecholamines (Zhu et al., [@B128]).

Another key player in the regulation of the cardiovascular systems are endothelin receptors. Endothelins are composed of a family of 21 amino acid peptides (ET-1, ET-2, and ET-3). ET-1 is the predominant endothelin in the cardiovascular system binding to endothelin A (ET~A~) and B (ET~B~) receptors (Sakurai et al., [@B102]). ET~A~ and ET~B~ have been reported to form heteromers, which induce sustained calcium signaling as compared to the corresponding homomers, known to induce a more transient calcium release in transfected HEK293 cells (Evans and Walker, [@B42]).

Serotonin was found in multiple cardiovascular tissues, including heart, blood vessels, brain, platelets, adrenal gland, and kidney. 5-HT~4~ (mainly 5-HT~4b~), 5-HT~2A~, and 5-HT~2B~ receptors coexist in auricular myocytes of newborn rats. 5-HT~4~ and 5-HT~2~ receptors appear to regulate intercellular communication at rat cardiac myocyte gap junctions. Unexpectedly, 5-HT~4~ activation reduces cAMP, L-type calcium currents, and intercellular coupling while 5-HT~2A~ or 5-HT~2B~ activation enhances gap junctional intercellular communication (Derangeon et al., [@B38]). These results suggest receptor heteromerization, which are still to be assessed.

Prostacyclin (PGI~2~) and Thromboxane A2 (TxA~2~) are biological opposites: PGI~2~ is a vasodilator and inhibitor of platelet aggregation, which limits the deleterious actions of TxA~2~, a vasoconstrictor, and platelet activator. The molecular mechanisms involved in the counter-regulation of PGI~2~ and TxA~2~ promoted signaling are unclear. Physical and functional interaction between the PGI~2~ receptor (IP~1~) and TxA~2~receptor (TP) were reported *in vitro* in HEK293 cells. IP~1~ seems to facilitate TP-mediated generation of cAMP in a manner independent of IP~1~-induced cAMP formation (Wilson et al., [@B122]).

Opioid receptors and β~2~ARs have been shown to coexist and functionally interact in cardiac myocyte sarcolemma. Low doses of selective opioids are known to inhibit norepinephrine-mediated functions (Pepe et al., [@B87]). Physical interaction was reported by co-immunoprecipitation studies in CHO cells exogenously expressing both receptors. *In vitro*, heteromerization results in an alteration of trafficking properties with no significant alterations in ligand binding. Moreover, opioid-selective agonists alter β~2~AR internalization, thus providing a possible molecular mechanism for the lack of β~2~AR agonist-mediated effects after OR activation (Jordan et al., [@B65]).

Prostanoids EP~1~ receptors and β~2~AR form heteromers *in vitro* (BRET, co-immunoprecipitation). EP~1~ and β~2~AR colocalize in airway smooth muscle cells, where activation of EP~1~ was reported to reduce β~2~AR-stimulated cAMP without affecting β~2~AR phosphorylation or trafficking. EP~1~/β~2~AR heteromers might be implicated in asthma (McGraw et al., [@B78]).

P2Y receptors play various physiological roles, including mediation of vasodilatation in the endothelium, vasoconstriction of smooth muscles, and control of mitogenic actions and secretory processes. A~2A~/P2Y~1~ and A~2A~/P2Y~12~ heteromers were detected in human platelet membranes by co-immunoprecipitation techniques, and seem to have a crucial role in the physiology of platelet aggregation (Nakata et al., [@B82]).

GPCR heteromers in taste
------------------------

Taste, or gustation, is mediated by a specialized anatomically and physiologically defined chemosensory gustatory system. The gustatory system in mammals includes taste receptor cells (TRC) organized in taste buds located within the gustatory papillae, located mainly, but not exclusively in the tongue. Reception of taste qualities that humans describe as sweet, umami, and bitter involves GPCRs from the T1R and T2R subfamilies (Bachmanov and Beauchamp, [@B7]). Whereas T1R are typical class C GPCRs with a large N-terminal "Venus fly trap" (VFT) domain, T2R belong to rhodopsin-like class A GPCRs with small N-terminal domains. The T1R family is composed of three subtypes T1R1, T1R2, and T1R3 that have been shown to form obligatory T1R1/T1R3 and T1R2/T1R3 heteromers (Nelson et al., [@B84], [@B83]). Binding of sweet stimuli such as sucrose or aspartame to the VFT of T1R2 and umami taste stimuli such as [l]{.smallcaps}-glutamate to the orthosteric binding site of the VFT of T1R1 activate T1R2/T1R3 and T1R1/T1R3 heterodimers, respectively (Nelson et al., [@B84], [@B83]; Xu et al., [@B124]). Several molecules binding to allosteric binding site within the VFT domain or the TM domain of taste receptors have been characterized.

For example, IMP and GMP bind near the opening of the orthosteric glutamate binding site of T1R1 thus further stabilize the closed conformation of the VFT (Zhang et al., [@B127]). Newly developed enhancers of sweet taste bind to a similar site in the T1R2 stabilize the sucrose-promoted closure of the VFT (Zhang et al., [@B126]). Such compounds could help reduce the caloric content in food and beverages. Other compounds such as lactisole and cyclamate have been proposed to bind to allosteric binding site located in the TM domain of T1R3 and thus regulate orthosteric ligand binding to the VFT of T1R1 and T1R2 in the respective heterodimers.

Much less is known about the T2R subfamily that comprises approximately 40 members in humans (Bachmanov and Beauchamp, [@B7]). T1R and T2R are expressed in distinct subsets of TRC excluding any functional crosstalk at the cellular level. However, nearly all T2R members are typically co-expressed within individual TRCs suggesting signal integration at the cellular level. The existence and potential functional importance of T2R heteromers remains to be studied.

GPCR heteromers in reproduction
-------------------------------

Different GPCRs participate in reproductive functions at the level of the hypothalamic--pituitary axes and reproductive organs. Oxytocin is a hypothalamic hormone stored in the posterior pituitary, which has uterine-contracting and milk-releasing actions. The receptor for oxytocin, OT, has been shown to cluster into homomers but also into heteromers with closely related vasopressin V~1A~ and V~2~ receptors in transfected HEK293 cells (Terrillon et al., [@B111]). The existence of OT homomers has been recently confirmed in mammary gland tissue using classical radioligand binding assays and a newly developed time-resolved FRET assay between two fluorescently labeled OT ligands (Albizu et al., [@B4]). In contrast to previous energy transfer assays that require expression of modified receptors fused to energy donors and acceptors, this novel assay can be applied to unmodified wild-type receptors and is thus likely to boost research on GPCR homo- and heteromerization in native tissues (Figure [2](#F2){ref-type="fig"}).

![**Detection of homo/heteromer formation by FRET using fluorescent ligands**. **(I)** In the case of homomer formation a FRET signal can be detected between a selective donor (D) ligand I that binds the first protomer and a selective acceptor (A) ligand 1 that binds the second protomer The donor and acceptor ligands can be the same molecule but labeled differently. **(II)** In the case of heteromer formation, a FRET signal can be detected between a selective donor ligand 1 that binds the first protomer and a selective acceptor ligand 2 that binds the second protomer. In this case, donor and acceptor ligands are different molecules.](fendo-02-00002-g002){#F2}

The luteinizing hormone (LH) is produced by the anterior pituitary gland. Whereas LH stimulates testosterone production in Leydig cells in males, it triggers ovulation in females. LH constitutes together with the follicle-stimulating hormone (FSH) and the thyroid-stimulating hormone (TSH) the glycoprotein hormone family. Their respective receptors LHR belong to a distinct subgroup of GPCRs that are characterized by a large N-terminal ligand binding domain-containing leucine-rich repeats and the typical heptahelical transmembrane domain. Biophysical and pharmacological assays were employed to show the formation of LHR homomers that display negative cooperativity between the ligand binding sites of receptor protomers (Urizar et al., [@B116]). More recently, the existence and functional relevance of LHR homomers was shown *in vivo* by using an elegant trans-complementation assay (Rivero-Muller et al., [@B97]). By generating transgenic mice co-expressing signaling deficient and ligand binding deficient forms of the LHR with targeted deletion of the wild-type LHR, the authors succeeded in completely restoring normal gonadal and genital function. This study provides compelling *in vivo* evidence for GPCR oligomerization by intermolecular functional complementation of two mutant receptors (Figure [3](#F3){ref-type="fig"}).

![**G protein-coupled receptors oligomerization by intermolecular functional complementation of mo mutant receptors**. **(I)** Oligomerization of ligand binding deficient receptor mutant (R^L−^) does not trigger GPCR function. **(II)** Oligomerization of signaling deficient receptor mutant (R^s−^) does not trigger GPCR function**. (III)** Co-expression of R^L−^ and R^s−^ restores GPCR function. L; ligand.](fendo-02-00002-g003){#F3}

Follicle-stimulating hormone, another hormone produced by the anterior pituitary gland, acts synergistically with LH to regulate pubertal maturation and reproductive processes. Based on the recent resolution of the crystal structure of FSH together with ectodomain of its receptor (FSHR) suggested formation of a tetrameric complex composed of a FSH dimer that bridges two FSHR ectodomains (Fan and Hendrickson, [@B43]). Such complexes were observed in the crystals and in solution, at high concentrations (μM range), suggesting the possible stabilization of FSHR oligomers in the presence of FSH. Subsequent studies did not confirm a major role of FSH binding and/or the ectodomain in oligomerization of the FSHR but pointed rather to the central role of the TM domain in stabilizing constitutive oligomers (Guan et al., [@B53]).

The existence of FSHR dimers inspired chemists to synthesize FSHR antagonist composed of two pharmacophores connected through ethylene glycol spacers (Bonger et al., [@B17]). These antagonists were indeed more potent than dimeric compounds in which one of the pharmacophores was replaced by an inactive confomer.

The gonadotropin-releasing hormone (GnRH) is produced in the hypothalamus and responsible for the release of FSH and LH from the anterior pituitary. Oligomerization of human GnRH receptors has been documented in transfected cells but remain still controversial *in vivo* (Pfleger et al., [@B89]). Convincing evidence for GnRH receptor heteromerization has been gathered in the protochordate *Ciona intestinalis*, which expresses six GnRH isoforms (tGnRH-3 to -8) and four GnRH receptor subtypes (R1-4). Heteromerization between R1, which binds to tGnRH-6, and the orphan R4 has been demonstrated in *Ciona* ovaries in co-immunoprecipitation experiments (Sakai et al., [@B101]). Importantly, tGnRH-6-induced ERK1/2 activation of R1 was robustly potentiated in the presence of R4 most likely originating from R1/R4 heteromerization.

GPCR heteromers in metabolism
-----------------------------

The increasing prevalence of obesity is responsible for the dramatic increase in the number of scientific and clinical studies on the control of energy homeostasis. Regulation of energy balance relies on a well-orchestrated communication between the CNS and peripheral organs. Many GPCRs, including cannabinoid, ghrelin, and melanocortin (MC) receptors, play a central role in the regulation of lipid metabolism and are therefore of major interest for drug development. In the current chapter, we will discuss some examples of GPCR heteromerization, which might be implicated in energy metabolism and related diseases as type 2 diabetes and obesity.

The endocannabinoid system comprises the enzymatic machinery for endocannabinoid synthesis and degradation, and cannabinoid CB~1~ and CB~2~ receptors. The endocannabinoid system controls energy balance and lipid metabolism centrally, in the hypothalamus and mesolimbic pathways, and peripherally, in adipocytes, liver, skeletal muscle, and pancreatic islet cells, acting through numerous anorexigenic and orexigenic pathways. Obese people display an increased endocannabinoid tone, driving CB~1~ in a feed-forward dysfunction. Several CB~1~ antagonists/inverse agonists were developed for the treatment of obesity. However, beside their efficiency in reducing food intake, these drugs were not devoid of side effects like psychiatric disorders and suicide (Bermudez-Silva et al., [@B13]). Orexins are orexigenic mediators selectively expressed in the hypothalamus, within neurons of the lateral hypothalamic area. Orexin A is involved in food intake in satiated rats but also in the regulation of drinking behavior. Co-expression of CB~1~ and the orexin OX~1~ receptor in CHO cells enhances the potency of orexin A to stimulate ERK kinase phosphorylation, and this effect was blocked by addition of SR-141716A, a CB~1~ antagonist (Hilairet et al., [@B57]). FRET assays indicate that CB~1~ and OX~1~ can form heteromers *in vitro* in CHO cells exogenously expressing these receptors. Heteromer formation was shown to modulate receptor distribution *in vitro* (Ellis et al., [@B40]).

Ghrelin plays an important role in energy homeostasis (Castaneda et al., [@B25]). It is synthesized by the stomach and is believed to exert the majority of its actions through the ghrelin receptor (GHSR), which is present in high density in both the hypothalamus and the pituitary gland. Neurotensin is a 13-amino acid neurohormone, located in the synaptic vesicles and released from the neuronal terminals in a calcium-dependent manner. It plays an important role in the physiology of pain-induction, central blood pressure control, and inflammation. There are three known neurotensin receptors, NTS~1~, NTS~2~, NTS~3~ but only NTS~1~ and NTS~2~ belong to the GPCR family (Stolakis et al., [@B107]). GHSR and NTS~1~ are shown to physically interact *in vitro* and neuromedin U was described as ligand for this heteromer. GHSR/NTS~1~ heteromers have been suggested to play a role for an autocrine growth-promoting pathway in non--small cell lung cancers by modulating the transcription of downstream target genes including the Forkhead box protein M1 **(**FOXM1; Takahashi et al., [@B108]).

Jiang et al. ([@B62]) identified neurons co-expressing GHSR and D~1~ in *GHSR-IRES-tauGFP* mice, suggesting at least a functional interaction between these two receptors. *In vitro*, the activation of GHSR by ghrelin amplifies dopamine/D~1~-induced cAMP accumulation (Jiang et al., [@B62]). *In vivo*, ghrelin and dopamine crosstalk was suggested based on the observation in rats that ghrelin administration increased dopamine-related hyperactivity (Wellman et al., [@B119]). Till date, there is no direct evidence *in vitro* or *in vivo* confirming GHSR/D~1~ heteromerization. GHSR can constitutively hetero-oligomerize with members of the prostanoid receptor family. GHSR is reported to heteromerize with EP~3-I~, IP~1~, and TPα receptors *in vitro* using BRET and co-immmunoprecipitation. The constitutive activation of phospholipase C by GHSR was significantly decreased in HEK 293 cells co-transfected with EP~3-I~, IP, or TPα. Moreover, cell surface expression of GHSR was reduced in presence of the prostanoids receptors (Chow et al., [@B28]). Despite lack of direct evidence, the expression of GHSR and prostanoid receptors in atherosclerotic plaques suggests heteromer implication in this pathology (Gomez-Hernandez et al., [@B51]).

Melanocortin receptors have a diverse range of physiological functions; MC~1~ controls skin pigmentation, MC~2~, the receptor for the adrenocorticotropic hormone (ACTH), plays a critical role in the hypothalamic--pituitary--adrenal axis, whereas MC~3~ and MC~4~ have essential roles in energy homeostasis and MC~5~ is believed to be involved in exocrine function (Cone, [@B34]). Mutations in the *MC4R* gene are the most frequent monogenic cause of severe obesity. Biebermann et al. present an interesting mechanistic explanation why a particular heterozygous inactivating MC~4~ mutation leads to the development of extreme obesity by a dominant-negative effect. This dominant-negative effect of the D90N mutation is caused by a functionally altered wild-type MC~4~/D90N receptor heteromer. MC~4~ can actually form heteromers, at least *in vitro*, with a mutant MC~4~ D90N resulting in functional alterations as exemplified by the complete loss of activation of the G~s~/adenylyl cyclase pathways (Biebermann et al., [@B14]). In addition, MC~4~ can physically interact, *in vitro*, with GPR7. MC~3~ was shown to heteromerize with GHSR resulting in the modulation of MC~3~ trafficking (Rediger et al., [@B94]).

Conclusions and Perspectives
============================

G protein-coupled receptor oligomerization has been an intensely studied field of research over the last 20 years. There is a broad consensus that GPCR oligomerization is not necessary for efficient activation of heterotrimeric G proteins as monomeric receptors are sufficient to ascertain this basic function. In contrast, GPCR oligomerization appears to be important for allosteric regulation and fine-tuning of signaling and receptor trafficking. It is furthermore admitted that most if not all GPCRs can form oligomers in intact cells. The detailed knowledge of the dimerization interface of some receptors (Guo et al., [@B55]; Wu et al., [@B123]) will undoubtedly guide the development of such tools. The lack of adequate tools (specific high-affinity antibodies, specific ligands, etc.) to study GPCR oligomerization *in vivo* or tissues expressing endogenous receptors has hampered faster progress for a long time. However, by employing original methods and developing new pharmacological tools more and more convincing evidence for the existence of GPCR oligomers is now increasingly gathered. GPCR oligomers, in particular heteromers provide new opportunities for specific pharmacological intervention. Based on the restricted expression profile of heteromers compared to the corresponding homomers, heteromer-specific drugs are expected to be very specific and to have fewer side effects. However, the great potential of heteromers is only beginning to be exploited as only very few heteromer-selective compounds are known today. Identification of such compounds will not only be important for future drug development but will also be indispensable tools for the identification and characterization of these heteromers *in vivo*. GPCR oligomers do not exist as isolated functional entities. It is now well established that GPCRs are integral part of protein networks composed of GPCRs and GPCR-associated protein complexes (Daulat et al., [@B35], [@B36]; Bockaert et al., [@B16]). Learning more about the dynamics and tissue-specific composition of these clusters will undoubtedly provide new insights into the function of GPCR involved in neuroendocrinology.
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